Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 5 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Grace Therapeutics, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of GRCE: Q2 2024 compared with Q3 2024
MeasureQ2 2024Q3 2024Change
Holders12120
Shares2.15M2.12M−32.8K (−1.5%)
Value$6.30M$6.36M+$62.6K (+1.0%)

New holders (2)

Institutions that held Grace Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to GRCE in Q3 2024
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC16,147$48.4K0.00%
Tower Research Capital LLC (TRC)2,732$8.20K0.00%

Sold out (2)

Institutions that held Grace Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of GRCE in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Susquehanna International Group, LLP37,793$113.0K
IFP Advisors, Inc6$18